Genomic Testing in Breast Cancer: Clinical Applications and Best Practices - Episode 10
Key Takeaways and Future Directions: Genomic Assays in Breast Cancer Treatment
Panelists discuss how genomic assays have become essential tools in modern breast cancer treatment, preventing overtreatment by enabling customized treatment plans that determine not only whether patients need chemotherapy but also which specific agents they should receive and whether treatment should be given before or after surgery.
Clinical Case Scenarios and Concluding Remarks
Main Discussion Topics:
- Case scenario discussions for node-positive postmenopausal patients
- Approaches to large tumors in smaller breasts, with focus on breast conservation
- Synthesis of key takeaways about genomic testing utility
Key Points for Physicians:
- For a 64-year-old healthy patient with 1 positive lymph node and T1c tumor, a 21-gene assay would guide treatment decisions.
- For larger tumors in smaller breasts, genomic testing can help determine whether neoadjuvant chemotherapy or endocrine therapy would be more effective.
- Genomic assays have dramatically reduced unnecessary chemotherapy use while enabling tailored treatment approaches.
Notable Insights:
- Genomic testing results consistently outperform clinician predictions about tumor biology.
- For borderline breast conservation candidates, neoadjuvant endocrine therapy may be effective for select patients with favorable biology.
- Patient-specific factors including reconstruction timing, genetic testing results, and personal preferences influence the treatment decision process
Clinical Significance: Genomic testing has transformed breast cancer care by enabling personalized treatment decisions that balance efficacy and toxicity considerations, significantly reducing overtreatment while identifying patients who truly benefit from more aggressive approaches.
Related Content:
